NeuroDerm Announces 2015 Annual General Meeting of Shareholders
NeuroDerm Announces Lifting of FDA Clinical Hold on ND0612, a Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson’s Disease
NeuroDerm Announces Lifting of FDA Clinical Hold on ND0612, a Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson’s Disease
NeuroDerm Announces Lifting of FDA Clinical Hold on ND0612, a Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson’s Disease
NeuroDerm Files Annual Report on Form 20-F for the Year Ended December 31, 2014
NeuroDerm Files Annual Report on Form 20-F for the Year Ended December 31, 2014
NeuroDerm Announces Fourth Quarter and 2014 Fiscal Year Financial Results and Provides a Corporate Update
NeuroDerm to Announce Updated Topline Results of Phase II Study of ND0612L at the 67th Annual Meeting of the American Academy of Neurology
NeuroDerm to Announce Updated Topline Results of Phase II Study of Continuous, Subcutaneously-Delivered Levodopa/Carbidopa for the Treatment of Parkinson’s Disease at the 67th Annual Meeting of the American Academy of Neurology
NeuroDerm to Announce Updated Topline Results of Phase II Study of ND0612L at the 67th Annual Meeting of the American Academy of Neurology
NeuroDerm CEO to Present at Upcoming Investor Conferences
NeuroDerm announced that its CEO will present at the Cowen and Company 35th Annual Health Care Conference and the 27th Annual ROTH Conference.
NeuroDerm Announces Extraordinary General Meeting of Shareholders
NeuroDerm Announces Extraordinary General Meeting of Shareholders for Ratification of Election of External Directors and Adoption of Compensation Policy
NeuroDerm Announces Topline Results of Phase IIa Pharmacokinetic Study of ND0612H and ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson’s Disease
NeuroDerm Announces Topline Results of Phase IIa Pharmacokinetic Study of ND0612H and ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson’s Disease
NeuroDerm Announces Third Quarter 2014 Financial Results and Provides a Corporate Update
NeuroDerm Announces Third Quarter 2014 Financial Results and Provides a Corporate Update
NeuroDerm CEO to Present at Oppenheimer Healthcare Conference on December 10, 2014
NeuroDerm CEO to Present at Oppenheimer Healthcare Conference on December 10, 2014
NeuroDerm Announces Pricing of Initial Public Offering
NeuroDerm Ltd. today announced the pricing of its initial public offering of 4,500,000 ordinary shares. NeuroDerm shares are expected to begin trading on the Nasdaq Global Market on November 14, 2014 under the ticker symbol “NDRM.”
NeuroDerm Announces Launch of Initial Public Offering
NeuroDerm Ltd. today announced the launch of its initial public offering of 4,500,000 ordinary shares pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (SEC).
NeuroDerm Announces Positive Topline Results of Phase II, Placebo-Controlled Study of Continuous, Subcutaneously Delivered Levodopa/Carbidopa (ND0612L) in Patients with Moderate to Severe Parkinson’s Disease
Company also reports encouraging partial results from Phase IIa study of continuous, subcutaneously delivered high-dose liquid levodopa/carbidopa (ND0612H) therapy for advanced patients
Data presented at the Michael J. Fox Foundation 2014 Parkinson’s Disease Therapeutics Conference
NeuroDerm Announces Presentation of ND0612L Top-line Phase II Results and ND0612H Preliminary Interim Phase IIa Results at the 2014 Parkinson’s Disease Therapeutics Conference
NeuroDerm Announces Presentation of ND0612L Top-line Phase II Results and ND0612H Preliminary Interim Phase IIa Results at the 2014 Parkinson’s Disease Therapeutics Conference
NeuroDerm Ltd. Files Registration Statement for Proposed Initial Public Offering
NeuroDerm Ltd. Files Registration Statement for Proposed Initial Public Offering
NeuroDerm Announces Start of Phase 2a Study of Continuous Subcutaneous Liquid Levodopa/Carbidopa Administration for Patients with Severe Parkinson’s Disease
NeuroDerm Announces Start of Phase 2a Study of Continuous Subcutaneous Liquid Levodopa/Carbidopa Administration for Patients with Severe Parkinson’s Disease
NeuroDerm Secures $16 Million Financing Round
NeuroDerm Secures $16 Million Financing Round
NeuroDerm Announces Eligibility for European Union Centralized Procedure for ND0612H, a Novel Treatment for Advanced Parkinson’s Disease
NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson’s disease.
NeuroDerm Announces Enrollment in a Second Phase 2 Study of ND0612L, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson’s Disease
NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson’s disease.
NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinson’s Disease
NeuroDerm, Ltd. was informed today that it was awarded, for the second time, a grant of $1M by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) …